Aquirre C, Rodriguez-Sasiain J M, Navajas P, Calvo R
Department of Pharmacology, University of Basque Country, School of Medicine, Leioa (Vizcaya), Spain.
Eur J Drug Metab Pharmacokinet. 1988 Jan-Mar;13(1):23-6. doi: 10.1007/BF03189924.
Penbutolol is a not cardioselective beta-adrenergic blocking drug; it is lipid soluble and differs in its protein binding from the other members of its group because shows linkage to alpha 1-glycoprotein, with no detectable binding to albumin. AAG levels change during pregnancy and so the binding of [3H]-penbutolol was compared in 11 pregnant patients and in 10 healthy women. Binding was obtained by ultrafiltration and measurement of the free fraction by scintillation spectrometry. The free penbutolol fraction was significantly higher in the pregnant women than in the controls (6.06 +/- 0.34 compared with 3.55 +/- 0.29, P less than 0.001). The AAG levels in the pregnant women were significantly lower (0.40 +/- 0.03 g/l) than in the controls (0.77 +/- 0.06 g/l) (P less than 0.001) which showed a significant correlation with the bound/free penbutolol ratio (r = 0.61, P less than 0.005). On the other hand there was no significant correlation with the extent of penbutolol's protein binding even though the albumin levels were lower in the pregnant women (2.83 +/- 0.17 compared with 4.86 +/- 0.17; P less than 0.001). Penbutolol's nK1a for AAG was lower in pregnant women, and this suggests that the fall in AAG levels is not the only factor involved in the reduced binding of penbutolol in pregnancy.
喷布洛尔是一种非心脏选择性的β-肾上腺素能阻滞剂;它具有脂溶性,与该类药物的其他成员在蛋白质结合方面有所不同,因为它与α1-糖蛋白有联系,而与白蛋白无明显结合。妊娠期间AAG水平会发生变化,因此对11名孕妇和10名健康女性的[3H]-喷布洛尔结合情况进行了比较。通过超滤获得结合情况,并通过闪烁光谱法测量游离部分。孕妇中游离喷布洛尔部分显著高于对照组(分别为6.06±0.34和3.55±0.29,P<0.001)。孕妇的AAG水平显著低于对照组(0.40±0.03g/l与0.77±0.06g/l相比)(P<0.001),这与结合/游离喷布洛尔比率显著相关(r=0.61,P<0.005)。另一方面,尽管孕妇的白蛋白水平较低(分别为2.83±0.17和4.86±0.17;P<0.001),但与喷布洛尔的蛋白质结合程度无显著相关性。孕妇中喷布洛尔与AAG的nK1a较低,这表明AAG水平下降不是妊娠期间喷布洛尔结合减少的唯一因素。